Market Terminal

Get Full Access To
Market Terminal For Free

Real-time breakouts. AI-powered analysis. The terminal that levels the playing field.

Open Terminal

BreakoutsScreenerAI AnalysisCalendarsMarketsNewsletters

Market Terminal

Get Full Access To
Market Terminal For Free

Real-time breakouts. AI-powered analysis. The terminal that levels the playing field.

Open Terminal

BreakoutsScreenerAI AnalysisCalendarsMarketsNewsletters

Gilead Sciences, Inc. (GILD)

NASDAQ · Healthcare · Drug Manufacturers - General

Market Cap$160.88B

SectorHealthcare

IndustryDrug Manufacturers - General

52-Week Low$102.84

52-Week High$157.29

CEODaniel O'Day

IPO DateJan 22, 1992

Employees17,600

CountryUnited States

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Explore More Tools

Stock ScreenerFilter stocks by any criteria

Earnings CalendarTrack upcoming earnings dates

Market NewsReal-time financial news

Get Full Access To Market Terminal For Free

Get Full Access To Market Terminal For Free

Gilead Sciences, Inc. (GILD)

Explore More Tools

Get Full Access To
Market Terminal For Free

Get Full Access To
Market Terminal For Free